Healthy
Conditions
Brief summary
Primary Objective: To access the bioequivalence of meloxicam capsule 15 mg (Test, T) to meloxicam tablet 15mg (Reference, R) following oral administration. Secondary Objective: To investigate the safety and tolerability of meloxicam following a single dose of meloxicam capsule 15 mg vs. meloxicam tablet 15 mg under fasting conditions in healthy male Taiwanese subjects.
Interventions
DRUGMeloxicam capsule
DRUGMeloxicam tablet
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of signed written informed consent before enrolment into the study, ability to communicate with the investigators, and to understand and comply with the requirements of the study 2. Healthy adult male, aged between 20 and 40 years old 3. Body Mass Index (BMI) between 18.5 and 25, inclusive (BMI was calculated as weight in kilogram \[kg\]/height in meters2 \[m2\]). 4. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest x-ray and electrocardiogram. 5. No significant deviation from biochemistry including: aspartate transaminase (SGOT/AST), alanine transaminase (SGPT/ALT), gamma-glutamyl-transferase (GGT), alkaline phosphatase, total bilirubin, albumin, glucose, blood urea nitrogen (BUN), creatinine, uric acid, total cholesterol and triglyceride. 6. No significant deviation from normal hematology including: hemoglobin, hematocrit, white blood count (WBC) with differential, red blood count (RBC) and platelet count 7. No significant deviation from normal urinalysis including: pH, occult blood, glucose and protein.
Exclusion criteria
1. History of drug or alcohol abuse within the past one year 2. Medical history of allergic asthma or sensitivity to analogous drug 3. Evidence of chronic or acute infectious diseases from 4 weeks before the study 4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology. 5. Ongoing peptic ulcer and constipation 6. Planned vaccination during the time course of the study. 7. Taking any clinical investigation drug from 3 months before the study 8. Use of any medication, including herb medicine or vitamins from 4 weeks before the study 9. Blood donation of more than 500 ml within the past 3 months 10. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result 11. A positive test for HIV antibody
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the plasma concentration-time curve from 0 h to last concentration time (AUC0-tz) | 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72 and 96 hours after administration |
| Time to reach maximum plasma concentration (Tmax) | 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72 and 96 hours after administration |
| Plasma half-life estimated by (0.693/ kel) ( t ½) | 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72 and 96 hours after administration |
| Area under the concentration-time curve of the analyte in plasma over the time interval zero to infinity (AUC0-infinity) | 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72 and 96 hours after administration |
| Observed maximum measured concentration of the analyte in plasma (Cmax) | 0, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72 and 96 hours after administration |
Secondary
| Measure | Time frame |
|---|---|
| Drug induced changes in standard laboratory values | screening phase (at least 10hours fasting), before and 24 h following drug administration on each study day, within 14 days after completion of all two periods |
| Occurrence of adverse events | up to 33 days after first administration |
Outcome results
None listed